Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gruber

Showing results (221-230 of 355) with videos related to

Pageof 36
Sort By:
The Journal of Infectious Diseases|August 2, 2023
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 YearsShon Remich, Nicholas Kitchin, James Peterson, et al.
Vaccine|April 27, 2010
Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in GermanyDorothee M Kieninger, Kathrin Kueper, Katrin Steul, et al.
Vaccine|May 22, 2013
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccineLisa A Jackson, Alejandra Gurtman, Kathryn Rice, et al.
The Pediatric Infectious Disease Journal|October 30, 2012
Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccineKristina A Bryant, Alejandra Gurtman, Douglas Girgenti, et al.
Vaccine|November 9, 2024
Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster doseJames Peterson, Daniel Drazan, Beth Moughan, et al.
Journal of Thrombosis and Haemostasis : JTH|April 6, 2013
Endogenous t-PA-antigen is an independent predictor of adverse cardiovascular events and all-cause death in patients with atrial fibrillationM K Freynhofer, D F Draxler, S C Gruber, et al.
Vaccine|May 22, 2013
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adultsLisa A Jackson, Alejandra Gurtman, Martin van Cleeff, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 28, 2020
Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of AgeDonald Hurley, Carl Griffin, Mariano Young, et al.
Vaccine|March 11, 2014
Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of ageRichard N Greenberg, Alejandra Gurtman, Robert W Frenck, et al.
Biochemical and Biophysical Research Communications|February 4, 2017
C21orf57 is a human homologue of bacterial YbeY proteinsAnubrata Ghosal, Caroline Köhrer, Vignesh M P Babu, et al.
Pageof 36

Showing results (221-230 of 355) with videos related to

Sort By:
Pageof 36
The Journal of Infectious Diseases|August 2, 2023
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 YearsShon Remich, Nicholas Kitchin, James Peterson, et al.
Vaccine|April 27, 2010
Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in GermanyDorothee M Kieninger, Kathrin Kueper, Katrin Steul, et al.
Vaccine|May 22, 2013
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccineLisa A Jackson, Alejandra Gurtman, Kathryn Rice, et al.
The Pediatric Infectious Disease Journal|October 30, 2012
Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccineKristina A Bryant, Alejandra Gurtman, Douglas Girgenti, et al.
Vaccine|November 9, 2024
Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster doseJames Peterson, Daniel Drazan, Beth Moughan, et al.
Journal of Thrombosis and Haemostasis : JTH|April 6, 2013
Endogenous t-PA-antigen is an independent predictor of adverse cardiovascular events and all-cause death in patients with atrial fibrillationM K Freynhofer, D F Draxler, S C Gruber, et al.
Vaccine|May 22, 2013
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adultsLisa A Jackson, Alejandra Gurtman, Martin van Cleeff, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 28, 2020
Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of AgeDonald Hurley, Carl Griffin, Mariano Young, et al.
Vaccine|March 11, 2014
Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of ageRichard N Greenberg, Alejandra Gurtman, Robert W Frenck, et al.
Biochemical and Biophysical Research Communications|February 4, 2017
C21orf57 is a human homologue of bacterial YbeY proteinsAnubrata Ghosal, Caroline Köhrer, Vignesh M P Babu, et al.
Pageof 36